论文部分内容阅读
一、制备肺癌相关抗原的单抗 应用杂交瘤技术制备肺癌相关抗原单抗的先驱者是Minna博士。制备肺癌单抗有三种途径。(1)利用已建立的人肺癌细胞株和自身B淋巴瘤。用1～10×10~8癌细胞,有时并用佐剂,1～2周免疫1次。融合后,杂交瘤培养上清液与细胞株和自身淋巴细咆反应,选择不与共同抗原反应的抗体。Cutlita等用这种方法制备了主要与小细胞癌或非小细胞癌反应的抗体,有趣的是非小细胞癌单抗通常至少与数种非小细胞癌反应,而并非专一与某一类型反应。这提示了有关起源于细胞的重要生物学现象。根据这种方法,在抗体的结合方式定性后才确定
First, the preparation of monoclonal antibodies against lung cancer antigen hybridoma technology Lung cancer associated antigen monoclonal antibody was pioneered Dr. Minna. There are three ways to prepare lung cancer monoclonal antibody. (1) Utilization of established human lung cancer cell lines and self-B lymphoma. With 1 ~ 10 × 10 ~ 8 cancer cells, sometimes with adjuvant, 1 to 2 weeks of immunization. After fusion, the hybridoma culture supernatant reacts with the cell line and autologous lymphocytes and selects antibodies that do not react with the common antigen. Cutlita et al. Used this method to prepare antibodies that predominantly respond to small cell or non-small cell carcinoma. Interestingly, non-small cell carcinoma mAbs usually respond to at least several non-small cell carcinomas and not specifically to one type of response . This suggests important biological phenomena that originated in cells. According to this method, it is determined after the antibody is bound in a qualitative manner